Page 44 - MemoriaBBN-Eng

HORIZONTAL PROGRAMMES

CIBER BBN has participated in the following forums and took the opportunity to dis-

seminate its technological offer and to foster relationships that can result in future
collaborations:

• Eurobioimaging Stakeholder Meeting, Vienna, January 21-23, 2013.

•
2nd Informative Conference for the Promotion and Funding of Programmes for

Innovation in Biomedicine in the European Union up to the year 2020. Instituto de

Salud Carlos III, Madrid, February 6, 2013.

• BioEurope Spring, Barcelona, March 11-13, 2013.

•
6th Annual Conference of the Technological Platforms of Biomedical Research:

Innovative Medicinal Products, Nanomedicine, Health technology and Biotechno-
logical Markets, Madrid, March 21-23, 2013.

• Kick off meeting of IN2 Life Sciences, Amsterdam, April 12, 2013.

• The European CLINAM & ETPN Summit, Basel, Switzerland, June 23-26, 2013.

• Medical Imaging Conference, Hannover, Germany, September 2013.

•
General Assembly and Annual Event of the European Technological Platform of
Nanomedicine (ETPN), Grenoble, France, October 1-2, 2013.

• 5th Euro Bioimaging Stakeholder Meeting, Heidelberg, Germany, November 25-

26, 2013.

•
TERCEL – CIBER BBN Technical Meeting, Madrid, December 13, 2013.

This updated offer is available in technology supply and demand websites such as In-

noget, EEN (European Entreprise Network), SEINNOVA and CIBER-BBN’s website. The

technological offer is periodically updated.

Contacts with companies and potential shareholders

The company PRAXIS, has shown interest in the liposome patent entitled “Functional-

ized liposomes useful for bioactive compound delivery”. P201231020 (06/19/2012)” and

this results in the presentation of a project to the CIBER-BBN transfer programme (call
for proposal of the year 2013) in which commitment to invest in the project totalling

200,000 euros will be obtained for years 2014 and 2015 in the event of a grant (pending

resolution).

In the year 2012, a technology transfer contract was signed for transferring techno-
logy developed in the BIOSCAFF-EYE intramural project to the company FERRER Interna-

tional. Said project was under development with positive results throughout 2013. Three 13
CIBER-BBN research groups participate in the project which objective is to develop a new 20
T
drug based on advanced therapies for ocular surface reconstruction. By means of this R
PO
contract, the company makes a long-term investment to find the pre-clinical and clinical E
studies of potential drugs arising from the research.
L R
A
A licensing contract was signed with the company EBERS MEDICAL TECHNOLOGY NU
N
S.L, for the patent entitled “Device and method for encapsulating microfluidic systems” A
/
(application P201231532).
BN
B
CIBER-BBN is currently in different degree of contact with many enterprises and entities R-
which are fairly interested either in directly transferring its technologies or carrying out BE
CI
collaborative projects that will lead to results that can be transferred to the industry.

44